Genomic Valley Biotech Intrinsic Value
Genomic Valley Biotech (GVBL) median intrinsic value is ₹8.70 from 5 valuation models (range ₹9–₹27), vs current price ₹29.00 — -70.0% downside (Trading Above Calculated Value), margin of safety -100.0%. For current market price and key ratios, visit Genomic Valley Biotech stock price NSE.
GVBL Valuation Methods Summary — DCF, Graham Number & P/E
Genomic Valley Biotech intrinsic value across 5 models vs current price ₹29.00 — upside/downside and value range per method. Analyse Genomic Valley Biotech ownership structure to track promoter, FII and institutional holdings.
| Method | Type | Intrinsic Value | Range | Upside/Downside | Details |
|---|---|---|---|---|---|
| P/E Based Valuation | earnings | ₹8.70 | ₹6.96 - ₹10.44 | -70.0% | EPS: ₹0.10, Sector P/E: 22x |
| Book Value Method | asset | ₹26.67 | ₹24.00 - ₹29.34 | -8.0% | Book Value/Share: ₹13.33, P/B: 2.0x |
| PEG Ratio Method | growth | ₹8.70 | ₹7.83 - ₹9.57 | -70.0% | EPS Growth: 8.0%, Fair P/E: 6.4x |
| Growth Adjusted P/E | growth | ₹8.70 | ₹7.83 - ₹9.57 | -70.0% | Revenue Growth: 6.0%, Adj P/E: 15.5x |
| Graham Defensive Method | conservative | ₹8.70 | ₹7.83 - ₹9.57 | -70.0% | EPS: ₹0.10, BVPS: ₹13.33 |
GVBL Intrinsic Value vs Market Price — All Valuation Models
Genomic Valley Biotech fair value range ₹9–₹27 vs current market price ₹29.00 across 5 valuation models. Read Genomic Valley Biotech dividend payments for the complete payout history and dividend yield track record.
GVBL Intrinsic Value Analysis — Undervalued or Overvalued?
Genomic Valley Biotech median intrinsic value ₹8.70, current price ₹29.00 — Trading Above Calculated Value by 70.0%, margin of safety -100.0%.
What is the intrinsic value of GVBL?
Based on our comprehensive analysis using 5 different valuation methods, the estimated intrinsic value of Genomic Valley Biotech (GVBL) is ₹8.70 (median value). With the current market price of ₹29.00, this represents a -70.0% variance from our estimated fair value.
The valuation range spans from ₹8.70 to ₹26.67, indicating ₹8.70 - ₹26.67.
Is GVBL undervalued or overvalued?
Based on our multi-method analysis, Genomic Valley Biotech (GVBL) appears to be trading above calculated value by approximately 70.0%.
GVBL Financial Health — Key Ratios vs Industry Benchmarks
Genomic Valley Biotech financial ratios — ROE, debt-to-equity, profit margins and liquidity vs industry benchmarks and their impact on intrinsic value.
| Financial Metric | Current Value | Industry Benchmark | Assessment | Impact on Valuation |
|---|---|---|---|---|
| Operating Margin | 19.0% | Industry Standard: 20%+ | Above 10% | Indicates operational efficiency level |
GVBL Cash Flow Quality — Operating & Free Cash Flow
Genomic Valley Biotech operating cash flow, free cash flow, quality rating and sustainability score by period — key inputs to DCF intrinsic value calculation.
| Period | Operating Cash Flow | Free Cash Flow | Cash Flow Quality | Sustainability Score |
|---|---|---|---|---|
| March 2025 | ₹0 Cr | ₹0 Cr | Negative Cash Flow | 3/10 |
| March 2024 | ₹0 Cr | ₹0 Cr | Negative Cash Flow | 3/10 |
| March 2023 | ₹-1 Cr | ₹-1 Cr | Negative Cash Flow | 3/10 |
| March 2022 | ₹-2 Cr | ₹-2 Cr | Negative Cash Flow | 3/10 |
| March 2021 | ₹2 Cr | ₹1 Cr | Positive Free Cash Flow | 7/10 |